Day Zero Diagnostics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Day Zero Diagnostics was a Watertown, Massachusetts-based biotechnology company founded in 2016, co-founded by physician-scientist Melis Anahtar of Massachusetts General Hospital. It developed genome sequencing-based in-vitro diagnostics that used whole-genome sequencing and machine learning to identify pathogens and their antibiotic resistance profiles directly from blood samples, targeting bloodstream infections and sepsis. Its products included epixact and a clonality analysis offering, and it raised over $64 million in total funding.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Day Zero Diagnostics was founded in Watertown, Massachusetts, to build sequencing-based infectious disease diagnostics, co-founded by MGH physician-scientist Melis Anahtar.
- Product development
The company developed epixact and clonality analysis products, using genomic sequencing and machine learning to identify pathogens and antibiotic resistance profiles in hours rather than days.
- Acquired by bioMérieux
In June 2025, bioMérieux acquired the assets of Day Zero Diagnostics to add next-generation sequencing and machine learning capabilities for rapid genomic diagnosis of resistant pathogens and antimicrobial stewardship.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.